AUTHOR=Elgharbawy Fawzia M. , Karim Mohammed Yousuf , Soliman Dina Sameh , Hassan Amel Siddik , Sudarsanan Anoop , Gad Ashraf TITLE=Case report: Neonatal autoimmune lymphoproliferative syndrome with a novel pathogenic homozygous FAS variant effectively treated with sirolimus JOURNAL=Frontiers in Pediatrics VOLUME=Volume 11 - 2023 YEAR=2023 URL=https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2023.1150179 DOI=10.3389/fped.2023.1150179 ISSN=2296-2360 ABSTRACT=Background: The autoimmune lymphoproliferative syndrome (ALPS) is a rare disease characterized by defective FAS signaling, which results in chronic, non-malignant lymphoproliferation and autoimmunity accompanied by increased numbers of double-negative (DN)T cells (T-cell receptor αβ+ CD4–CD8–) and an increased risk of developing malignancies later in life. Case Presentation: We herein report a case of newborn boy with a novel germline homozygous variant identified in the FAS gene, exon 9, c.775del, which was considered pathogenic. The consequence of this sequence change was the creation of a premature translational stop signal (p. lle259*), associated with a severe clinical phenotype of ALPS-FAS. The elder brother of the proband is also affected by ALPS and has been found to have the same FAS homozygous variant associated with a severe clinical phenotype of ALPS-FAS, whereas the unaffected parents are heterozygous carriers of this variant. This new variant has not previously been described in population databases (gnomAD and ExAC) or in patients with FAS-related conditions. Treatment with Sirolimus effectively improved the patient clinical manifestations with obvious reduction in the "double negative" T cells percentage. Conclusion: We described a new ALPS-FAS clinical phenotype-associated germline FAS homozygous pathogenic variant, Exon 9, c.775del, that produces a premature translational stop signal (p. lle259*). Sirolimus significantly reduced the percentage of "double-negative" T cells, and substantially relieved the patient's clinical symptoms.